These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 22875102)

  • 1. CCR5 antagonism impacts vaccination response and immune profile in HIV-1 infection.
    Westrop SJ; Moyle G; Jackson A; Nelson M; Mandalia S; Imami N
    Mol Med; 2012 Oct; 18(1):1240-8. PubMed ID: 22875102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: effect on T cells latently infected.
    Gutiérrez C; Díaz L; Vallejo A; Hernández-Novoa B; Abad M; Madrid N; Dahl V; Rubio R; Moreno AM; Dronda F; Casado JL; Navas E; Pérez-Elías MJ; Zamora J; Palmer S; Muñoz E; Muñoz-Fernández MÁ; Moreno S
    PLoS One; 2011; 6(12):e27864. PubMed ID: 22174752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial.
    Hunt PW; Shulman NS; Hayes TL; Dahl V; Somsouk M; Funderburg NT; McLaughlin B; Landay AL; Adeyemi O; Gilman LE; Clagett B; Rodriguez B; Martin JN; Schacker TW; Shacklett BL; Palmer S; Lederman MM; Deeks SG
    Blood; 2013 Jun; 121(23):4635-46. PubMed ID: 23589670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maraviroc Intensification of cART in Patients with Suboptimal Immunological Recovery: A 48-Week, Placebo-Controlled Randomized Trial.
    van Lelyveld SF; Drylewicz J; Krikke M; Veel EM; Otto SA; Richter C; Soetekouw R; Prins JM; Brinkman K; Mulder JW; Kroon F; Middel A; Symons J; Wensing AM; Nijhuis M; Borghans JA; Tesselaar K; Hoepelman AI;
    PLoS One; 2015; 10(7):e0132430. PubMed ID: 26208341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized controlled clinical trial on the impact of CCR5 blockade with maraviroc in early infection on T-cell dynamics.
    Karris MY; Umlauf A; Vaida F; Richman D; Little S; Smith D
    Medicine (Baltimore); 2016 Nov; 95(44):e5315. PubMed ID: 27858912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequency and Env determinants of HIV-1 subtype C strains from antiretroviral therapy-naive subjects that display incomplete inhibition by maraviroc.
    Borm K; Jakobsen MR; Cashin K; Flynn JK; Ellenberg P; Ostergaard L; Lee B; Churchill MJ; Roche M; Gorry PR
    Retrovirology; 2016 Nov; 13(1):74. PubMed ID: 27809912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic Inhibition of R5 HIV-1 by the Fusion Protein (FLSC) IgG1 Fc and Maraviroc in Primary Cells: Implications for Prevention and Treatment.
    Latinovic OS; Zhang J; Tagaya Y; DeVico AL; Fouts TR; Schneider K; Lakowicz JR; Heredia A; Redfield RR
    Curr HIV Res; 2016; 14(1):24-36. PubMed ID: 26354735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of maraviroc on HIV disease progression-related biomarkers.
    Romero-Sánchez MC; Machmach K; Gonzalez-Serna A; Genebat M; Pulido I; García-García M; Alvarez-Ríos AI; Ferrando-Martinez S; Ruiz-Mateos E; Leal M
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5858-64. PubMed ID: 22948867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical utility of maraviroc.
    Parra J; Portilla J; Pulido F; Sánchez-de la Rosa R; Alonso-Villaverde C; Berenguer J; Blanco JL; Domingo P; Dronda F; Galera C; Gutiérrez F; Kindelán JM; Knobel H; Leal M; López-Aldeguer J; Mariño A; Miralles C; Moltó J; Ortega E; Oteo JA
    Clin Drug Investig; 2011; 31(8):527-542. PubMed ID: 21595497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry.
    Roche M; Jakobsen MR; Ellett A; Salimiseyedabad H; Jubb B; Westby M; Lee B; Lewin SR; Churchill MJ; Gorry PR
    Retrovirology; 2011 Nov; 8():89. PubMed ID: 22054077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maraviroc: a review of its use in HIV infection and beyond.
    Woollard SM; Kanmogne GD
    Drug Des Devel Ther; 2015; 9():5447-68. PubMed ID: 26491256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transmitted/founder and chronic HIV-1 envelope proteins are distinguished by differential utilization of CCR5.
    Parker ZF; Iyer SS; Wilen CB; Parrish NF; Chikere KC; Lee FH; Didigu CA; Berro R; Klasse PJ; Lee B; Moore JP; Shaw GM; Hahn BH; Doms RW
    J Virol; 2013 Mar; 87(5):2401-11. PubMed ID: 23269796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of maraviroc intensification on HIV-1-specific T cell immunity in recently HIV-1-infected individuals.
    Kawana-Tachikawa A; Llibre JM; Bravo I; Escrig R; Mothe B; Puig J; Puertas MC; Martinez-Picado J; Blanco J; Manzardo C; Miro JM; Iwamoto A; Pozniak AL; Gatell JM; Clotet B; Brander C;
    PLoS One; 2014; 9(1):e87334. PubMed ID: 24475275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiretroviral therapy in HIV-1-infected individuals with CD4 count below 100 cells/mm3 results in differential recovery of monocyte activation.
    Patro SC; Azzoni L; Joseph J; Fair MG; Sierra-Madero JG; Rassool MS; Sanne I; Montaner LJ
    J Leukoc Biol; 2016 Jul; 100(1):223-31. PubMed ID: 26609048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maraviroc: a review of its use in the management of CCR5-tropic HIV-1 infection.
    Perry CM
    Drugs; 2010 Jun; 70(9):1189-213. PubMed ID: 20518583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial.
    Serrano-Villar S; Sainz T; Ma ZM; Utay NS; Chun TW; Mann S; Kashuba AD; Siewe B; Albanese A; Troia-Cancio P; Sinclair E; Somasunderam A; Yotter T; Deeks SG; Landay A; Pollard RB; Miller CJ; Moreno S; Asmuth DM
    PLoS Pathog; 2016 Jan; 12(1):e1005381. PubMed ID: 26795282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir.
    Westby M; Lewis M; Whitcomb J; Youle M; Pozniak AL; James IT; Jenkins TM; Perros M; van der Ryst E
    J Virol; 2006 May; 80(10):4909-20. PubMed ID: 16641282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prime/boost immunization with HIV-1 MPER-V3 fusion construct enhances humoral and cellular immune responses.
    Bolhassani A; Kardani K; Vahabpour R; Habibzadeh N; Aghasadeghi MR; Sadat SM; Agi E
    Immunol Lett; 2015 Dec; 168(2):366-73. PubMed ID: 26518142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro effect of anti-human immunodeficiency virus CCR5 antagonist maraviroc on chemotactic activity of monocytes, macrophages and dendritic cells.
    Rossi R; Lichtner M; De Rosa A; Sauzullo I; Mengoni F; Massetti AP; Mastroianni CM; Vullo V
    Clin Exp Immunol; 2011 Nov; 166(2):184-90. PubMed ID: 21985364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5.
    Tilton JC; Wilen CB; Didigu CA; Sinha R; Harrison JE; Agrawal-Gamse C; Henning EA; Bushman FD; Martin JN; Deeks SG; Doms RW
    J Virol; 2010 Oct; 84(20):10863-76. PubMed ID: 20702642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.